ZVSA
Income statement / Annual
Last year (2023), ZyVersa Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, ZyVersa Therapeutics, Inc.'s net income was -$98.30 M.
See ZyVersa Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$10,400.00 |
$10,400.00 |
$10,400.00 |
$10,400.00 |
| Gross Profit |
-$10,400.00 |
-$10,400.00 |
-$10,400.00 |
-$10,400.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$3.21 M
|
$5.41 M
|
$2.12 M
|
$6.47 M
|
| General & Administrative
Expenses |
$11.21 B
|
$7.61 M
|
$5.58 M
|
$5.36 M
|
| Selling & Marketing
Expenses |
-$11.20 B
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$11.20 M
|
$7.61 M
|
$5.58 M
|
$5.36 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$14.41 M |
$13.01 M |
$7.70 M |
$11.83 M |
| Cost And Expenses |
$14.42 M |
$13.01 M |
$7.70 M |
$11.83 M |
| Interest Income |
$0.00 |
$427.54 |
$821.37 |
$516.45 |
| Interest Expense |
-$457,000.00 |
$427,542.00 |
$821,366.00 |
$516,450.00 |
| Depreciation &
Amortization |
$10,400.00
|
$10,400.00
|
$10,400.00
|
$10,400.00
|
| EBITDA |
-$107.74 M
|
-$11.67 M
|
-$7.25 M
|
-$12.16 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$93.33 M
|
-$2.37 M
|
-$379,785.00
|
-$850,108.00
|
| Income Before Tax |
-$107.75 M |
-$14.05 M |
-$8.08 M |
-$12.68 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$9.46 M |
$745.05 M |
$821,366.00 |
$516,450.00 |
| Net Income |
-$98.30 M |
-$759.10 M |
-$8.91 M |
-$13.20 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
| EPS |
-1089.67 |
-930.251 |
-173.656 |
-272.447 |
| EPS Diluted |
-1089.67 |
-930.251 |
-173.656 |
-272.447 |
| Weighted Average Shares
Out |
$97,503.00
|
$25,948.00
|
$46,552.00
|
$46,552.00
|
| Weighted Average Shares
Out Diluted |
$97,503.00
|
$25,948.00
|
$46,552.00
|
$46,552.00
|
| Link |
|
|
|
|
